25 results about "Ocular irritation" patented technology

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

The utility model discloses a cosmetic eye irritation detection and analysis device which comprises a base, and the right side of the top of the base is fixedly connected with an analysis device main body. Through the arrangement of the groove, the analysis device is started, the start button is pressed down to start the automatic sample dropping pipettor, after the automatic sample dropping pipettor drips a sample to a chick embryo chorioallantoic membrane in the groove under the automatic sample dropping pipettor, the stepping motor is automatically started and drives the rotating base plate to rotate by 36 degrees, and the chick embryo chorioallantoic membrane is automatically dropped into the chick embryo chorioallantoic membrane in the groove under the automatic sample dropping pipettor. The chick embryo chorioallantoic membrane in the next groove is moved to the position under the automatic sample dropwise adding pipettor for dropwise adding the sample, and a pause button is controllably pressed until the ten chick embryo chorioallantoic membranes are dropwise added completely, so that the stepping motor and the automatic sample dropwise adding pipettor stop working, and then the chick embryo chorioallantoic membranes can be covered with a preservative film for constant-temperature culture; the dripping process is automatically and quickly completed, so that the analysis efficiency is improved, the use of a user is facilitated, and the practicability of the analysis device is improved.

The present invention relates to an eye drop composition comprising imatinib. The present invention relates to an eye drop composition and a method for preparing same, in which the eye drop composition is prepared at a pH level suitable as an eye drop while an appropriate amount of an imatinib derivative is dissolved even within a relatively high pH range, compared to conventional compositions prepared under pH conditions (< pH 5.5) unsuitable for eye drop, in order to dissolve imatinib, and has improved phase stability, long-term stability, bioavailability, and eye irritation.

The invention relates to the technical field of cosmetics, in particular to a dandruff removing composition, a preparation method thereof and a nursing material. The anti-dandruff composition is prepared from the following components in percentage by weight: 0.1 to 5 percent of Mexican juniper oil, 0.5 to 8 percent of bitter oil tree seed oil, 1 to 10 percent of hydrogenated lecithin, 0.2 to 5 percent of phytosterol, 1 to 10 percent of natural emulsifier, 5 to 20 percent of natural vegetable fat, 0.2 to 5 percent of xanthan gum and the balance of water. According to the anti-dandruff cream, the bitter oil tree seed oil and the Mexican juniper oil are used as active ingredients, the stability and effectiveness of active matters are improved by utilizing a liposome technology, the skin permeability and the uniformity on scalp are improved, a better anti-dandruff effect is achieved, the safety is high, and skin irritation and eye irritation are avoided.

This invention belongs to the field of pharmaceutical formulations and relates to a compound ophthalmic in-situ gel composition for treating ocular Demodex mite infection, its preparation method, and its application. By weight percentage, the compound ophthalmic in-situ gel composition for treating ocular Demodex mite infection comprises 0.1-2.0% of a nitroimidazole compound, 0.05-3.0% of an isoxazoline compound, 0.1-1.5% of a gelling polymer, 1.0-8.0% of a complex solubilizing system, 0.1-3.0% of pharmaceutically acceptable excipients, and the balance being water. The complex solubilizing system includes polyvinylpyrrolidone and cyclodextrin derivatives. This invention effectively solves the problem of poor solubility of isoxazoline drugs through a complex solubilizing system, and the combination of the two drugs has a significant synergistic acaricidal effect. Combined with a gelling polymer, it can achieve in-situ gelation on the ocular surface, prolong retention, and sustained drug release, with low ocular irritation, providing a highly effective, long-lasting, and safe new local treatment option for Demodex mite-related eye diseases.

The invention provides a method for evaluating eye irritation of cosmetics, and relates to the technical field of detection. The method comprises the following steps: firstly, acquiring a first image of a chick embryo chorioallantoic membrane before contacting a to-be-detected sample; removing the to-be-detected sample contact film after a preset time to obtain a second image; performing color channel separation on the two images, and selecting a green channel image to perform gray value analysis to obtain a first gray value and a second gray value; and finally evaluating the eye irritation level of the sample to be detected according to the gray value difference. According to the method disclosed by the invention, quantitative evaluation on eye irritation is realized by utilizing the optical characteristic of chick embryo blood vessels to green light, the subjective defect that a traditional chick embryo chorioallantoic membrane test depends on visual inspection is overcome, the objectivity, accuracy and repeatability of a detection result are remarkably improved, the operation is simple and convenient, and animal ethical dispute is avoided.

The present invention provides a composition to increase tear production to relieve irritation from dry eyes, and a method for application of the composition. The composition includes at least 5% menthol and a carrier. The carrier comprises at least one of: a triglyceride oil, a medium chain triglyceride, petroleum jelly, coconut oil, olive oil, beeswax, a wax that is semi-solid at 21 C, a vegetable wax, an animal wax, a petroleum wax, a mineral wax, a synthetic wax, vaseline, lanoline, hydrogenated rosin / glyceryl diisostearate, hydrogenated polyisobutene, polyethylene, fatty acid cholesteryl, higher fatty acid esters, aliphatic alcohols, squalene, polyethyleneglycol, higher fatty acids, animal oil, and vegetable oil. The method includes delivering the composition to a user's eye.

The application discloses a kind of semi-fluorocarbon for removing emulsified silicone oil filling and its preparation method and application, comprising, olefin and perfluoroalkyl iodine are dissolved in acetonitrile, initiator is added and reacted under light source, to obtain fluorine-containing iodoalkane;Fluorine-containing iodoalkane is dissolved in isopropyl alcohol, and after adding reducing agent and heating reaction, it is washed to obtain semi-fluorocarbon with the structure of CF3 (CF2) 3 (CH2) 4CH3, named semi-fluorinated nonafluorononane;Wherein, the molar ratio of the olefin and perfluoroalkyl iodine is 1:1-1.4, and the initiator is cuprous chloride.The application controls the proportion of raw materials, carries out reaction under the condition of suitable initiator, simultaneously preferably zinc powder is used as reducing agent, effectively improves product purity and product yield, and operation process is simple, safe, and CF3 (CF2) 3 (CH2) 4CH3 prepared has not only good stability, but also good biocompatibility, no cytotoxicity, no skin sensitization, no acute eye irritation, can dissolve or wrap emulsified silicone oil droplets, and play a great role in the removal of emulsified silicone oil.

The invention relates to the field of pharmaceutical preparations, in particular to an ophthalmic composition containing cyclosporine. The ophthalmic composition comprises a first component and a second component, wherein the first component is ciclosporin or a pharmaceutically acceptable salt or a pharmaceutically acceptable derivative thereof; and a second component, wherein the second component is selected from at least one of alkyl glycoside and polyethylene glycol-15-hydroxystearate. The cyclosporine composition disclosed by the invention is good in stability, and repeated administration results show that the composition is free from eye irritation, so that the safety and the patient compliance are greatly improved. Meanwhile, the preparation process of the cyclosporine composition is simple, batch production can be realized through a conventional ophthalmic preparation production line, and the cyclosporine composition is beneficial to popularization and application in actual production.

The invention relates to the field of contact lens care, in particular to a hydrogen peroxide care solution suitable for a platinum alloy neutralization ring. The care solution is prepared from the following components in parts by weight: 20 to 50 parts of hydrogen peroxide, 7.6 to 11.3 parts of borate buffer agent, 0.1 to 0.5 part of chelating agent, 6 to 12 parts of nano inclusion solution, 20 to 40 parts of solubilizer, 0.01 to 0.05 part of antioxidant, 5 to 10 parts of regulator and 1000 parts of distilled water. The hydrogen peroxide care solution provided by the invention is suitable for a platinum alloy neutralization ring, and a hydrogen peroxide stabilizing system, a dibazol slow-release system and other auxiliaries are added into the hydrogen peroxide care solution. The care solution can prolong the life of a platinum ring, and the corrosion rate of platinum alloy is reduced by more than 50%; the production of strong acid neutralization products is avoided, and the eye irritation is reduced; in addition, the antibacterial broad-spectrum property is also realized.

The invention discloses an oral antibacterial liquid for an oral antibacterial mucoprotective film, which has an excellent inhibition effect on escherichia coli, porphyromonas gingivalis, staphylococcus aureus, streptococcus mutans and candida albicans through the synergistic effect of lysozyme, lysostaphin, angelia and plant extract. The bacteriostasis rate can reach 99.99% or above after 5 minutes of action; through a specific ratio and a specific process, after the active ingredients in the product are subjected to an accelerated test at 37 DEG C for 90 days, the activity decline rate of lysozyme and lysostaphin is lower than 10%, the color and precipitation are not changed, the validity period of the product can stably reach 2 years, and the efficacy in the shelf life is ensured; an acute eye stimulation test verifies that the product has no stimulation to New Zealand rabbit eyes, which indicates that the product is safe and mild when being used for oral mucosa, and stimulation and side effects possibly brought by a chemical bacteriostatic agent are avoided.

This invention relates to a tobramycin eye drop. Specifically, this invention provides a tobramycin eye drop comprising tobramycin, polyethylene glycol 400, glycerin, sorbitol, alanine, hydroxypropyl cellulose, sodium dihydrogen phosphate, disodium hydrogen phosphate, and water. The tobramycin eye drop of this invention has the advantage of low ocular irritation, significantly improving ocular drug administration compliance. Furthermore, the tobramycin eye drop of this invention exhibits excellent light and high-temperature stability, ensuring the quality and safety of the tobramycin eye drop, thereby enhancing its application value.

The present invention relates to an ophthalmic preparation and the use thereof. Specifically, the present invention relates to a pilocarpine ophthalmic preparation and the use thereof in the treatment of ocular diseases. The pilocarpine ophthalmic preparation provided in the present invention has the beneficial effects of a good stability and low ocular irritation.

The present invention relates to a nanoemulsion ophthalmic composition and a preparation method thereof, wherein the nanoemulsion ophthalmic composition is obtained by mixing cyclosporine, castor oil, hydrophilic and hydrophobic emulsifiers, menthol, and an aqueous solvent, and thus exhibits excellent stability as well as ameliorating ocular irritation such as a feeling of grittiness, blurry vision, and the like.

The invention relates to the technical field of daily chemical cleaning and nursing, and discloses a silicone oil-free sulfate-free weak cation system shampoo and a preparation method thereof.According to the formula of the shampoo, lauramide propyl betaine, sodium lauroyl sarcosinate and other multi-element surfactants are compounded; a weak cation conditioning system cooperatively constructed by matching phytosterols, cationic cellulose and cationic guar gum does not contain silicone oil and sulfate components; gradient temperature change and segmented pH regulation and control processes are adopted for preparation. The product has a pH value of 5.0-6.0, conforms to the scalp environment, does not have harmful residues such as D4 and dioxane, has acute eye irritation of slight irritation, has a cleaning rate of 91-97%, is fine and smooth in foam and easy to wash, can significantly improve the smoothness of wet and dry hair and reduce frizz, has stable performance after being placed at 60 DEG C for 4 months, has mild property, cleaning power, repairing effect and use experience, and is suitable for various hair qualities.

The present invention provides an ophthalmic preparation for correcting near vision, its preparation method and use, which are particularly suitable for treating presbyopia and mild hyperopia. The ophthalmic preparation contains pilocarpine, brimonidine, a compound containing a stin nucleus group structure, a non-steroidal anti-inflammatory drug, functional excipient A, a thickening agent, a complexing agent, a pH regulator, a bacteriostatic agent and sodium chloride. The experimental results show that the compound containing a stin nucleus group structure added to the ophthalmic preparation of the present invention has a synergistic effect with pilocarpine and brimonidine. In addition, adding functional excipient A to the ophthalmic preparation reduces the irritation of the preparation and improves the patient compliance. Compared with the commonly used drugs of the same kind clinically, the ophthalmic preparation of the present invention has the characteristics of higher efficacy and lower ocular irritation.

A cell-based device and method are disclosed for in vitro testing of compositions or compounds for irritation potential. Both the device and method comprise a) a confluent layer of corneal epithelial cells supported on a chemically patterned hydrogel, where the cells are aligned with the chemical pattern, b) a collector to receive effluent fluid, and optionally c) a detector. The device and method can also comprise an extracellular matrix (ECM) assembled by corneal keratocytes supported on the chemically patterned hydrogel. The cell-based device and method provide simple replacements for the in vivo Draize rabbit eye irritation test.

The present invention concerns an in vitro test for detecting the irritant potential of chemicals combining a corneal cell model with a selection of predictive and qualitative molecular markers to classify compounds into 3 categories, namely irreversible eye damage 21 days after application (category 1), reversible eye damage 21 days after application (category 2) and no irritation (no category). The inventors have thus demonstrated that the response following the action of an irritant substance occurs directly on an in vitro reconstructed corneal epithelium, and that the degree of irritation and the qualification of this irritation of a molecule may be determined by the use of specific biomarkers of eye irritation.

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (DoI) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

The present invention belongs to the technical field of surfactant preparation, and specifically relates to a surfactant complex with reduced eye irritation. The preparation method provided by the present invention includes the following steps: mixing aminocyclodextrin, sodium cocoyl amphoacetate and water, performing ultrasonic treatment after mixing, adding lactic acid to the mixed solution, heating and stirring, cooling, adding capryloyl / capryl amidopropyl betaine, sodium methyl cocoyl taurate and glycolipid, and stirring and mixing to obtain the surfactant complex; the mass ratio of aminocyclodextrin, sodium cocoyl amphoacetate and water is (3-7):(20-30):(50-70); the mass ratio of aminocyclodextrin and lactic acid is (4-8):(0.2-1); the mass ratio of sodium cocoyl amphoacetate, capryloyl / capryl amidopropyl betaine, sodium methyl cocoyl taurate and glycolipid is (20-30):(3-7):(2-5):(2-5). The surfactant complex prepared by the present invention has high viscosity and stability.

The present invention provides a detection method and a detection system for an active disinfection and sterilization device without chemical consumables that can coexist with humans. The detection method includes: Step A, placing the active disinfection and sterilization device in a test chamber, and after starting the device and running for a first period of time, performing: Step A1, measuring the concentration of by-products on the disinfection and sterilization factor output channel of the active disinfection and sterilization device; Step A2, collecting the disinfection and sterilization factors output by the active disinfection and sterilization device to obtain a liquid of disinfection and sterilization factors, and performing an acute inhalation toxicity test and / or a skin irritation test and / or an acute eye irritation test on the liquid of disinfection and sterilization factors. Testing in a clean and airtight test chamber can reduce the interference of the external environment and improve the test accuracy; this detection method not only detects the concentration of by-products, but also detects the harm of the disinfection and sterilization factors output by the active disinfection and sterilization device that directly acts on the human body, and can comprehensively and accurately evaluate the advantages and disadvantages of the human-machine coexistence of the active disinfection and sterilization device without chemical consumables, making the active disinfection and sterilization device safer and more reliable.

The invention belongs to the technical field of medical cosmetology, and discloses a melting-eliminating high-content salicylic acid composition as well as a preparation method and application thereof. The composition comprises salicylic acid, polyethylene glycol-8 and PPG-14-polyglycerol-2-ether, the weight fraction ratio of the salicylic acid to the polyethylene glycol-8 to the PPG-14-polyglycerol-2-ether is 3: (4-6): (1-3), and the weight percentage of the salicylic acid in the composition is 25%-30%. According to the composition disclosed by the invention, polyethylene glycol-8 and PPG-14-polyglycerol-2-ether in a specific proportion are taken as cofluxing agents, a stable homogeneous system is formed after the cofluxing agents and salicylic acid are co-melted, no salicylic acid melting peak exists in DSC scanning, and the problems that salicylic acid is poor in solubility and easy to crystallize and separate out in a formula are solved. The composition has good mildness, is not added with an organic solvent, a pH regulator and other components, and is verified by rabbit acute eye irritation tests and multiple skin irritation tests to be non-irritant. The preparation process is simple and easy to operate, and industrial production is facilitated.

This eye drop contains (A) 0.02-0.15 w / w% (inclusive) of a 2-methacryloyloxyethyl phosphorylcholine-dimethylacrylamide-stearyl methacrylate copolymer in which the molar ratio of structural units represented by formula (1) is a: b: c = 100: 10-400: 2-50, (B) 0.000001-0.0001 w / w% (inclusive) of polyhexamethylene biguanide represented by formula (2) or a salt thereof, and (C) 0.02 to 2.0 w / w% (inclusive) of polyoxyethylene polyoxypropylene glycol, and the content of sodium chloride is 0.3 w / w% or less. According to the present invention, it is possible to provide an eye drop which imparts lubricity to the cornea surface, has sufficient storage efficacy, and has low eye irritation.

To provide a method for manufacturing a partial plating product that can improve the working environment of a person, and that can peel off a masking agent in a short time even if the peeling agent is safe for the human body after plating, and to provide a partial plating product. 【Solution means】An oil-based ink containing rosin resin and alcohols as main components is used as a masking agent to form a coating film layer 20 on a plating base material 10, and by volatilizing the alcohols from the coating film layer, a consolidated film 30 mainly composed of rosin resin is formed. Further, a plating layer 50 is formed on the portion of the plating base material where there is no consolidated film by plating treatment with an acidic bath that does not dissolve the consolidated film. Alcohols have less eye irritation and irritating odor than thinners, are safe for the human body, so the working environment can be improved, and a consolidated film can be formed in a short time. Also, the rosin resin forming the consolidated film can be easily peeled off with alcohols.

The invention belongs to the field of pharmaceutical compositions, and particularly relates to an emulsion containing a nitrogen-containing heterocyclic compound and a preparation method of the emulsion. The emulsion contains active ingredients, vegetable oil, an emulsifier, hydroxy propyl cellulose and water, has a good drug effect in the aspect of relieving xerophthalmia, has better uniformity and stability, and is beneficial to ensuring the effectiveness and safety of the drug in the storage and use processes. Meanwhile, the ophthalmic emulsion composition can prolong the residence time of the active ingredients in eyes, improve the bioavailability of the medicine and reduce cytotoxicity and eye irritation.